Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

RIDGEFIELD, N.J.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced a strategic collaboration with SHL Medical, a leading provider of advanced drug delivery systems, alongside an expansion of sterile fill-finish and autoinjector final assembly capacity at its Ridgefield, NJ site. Together, these investments establish a fully integrated U.S.-based offering spanning sterile manufacturing, device assembly and commercial packaging for drug-device c.

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced the completion of its acquisition of Clario Holdings, Inc., a leading provider of endpoint data solutions for clinical trials, for $8.875 billion in cash, plus potential additional earnout and other payments, largely dependent on performance. With the transaction complete, the Clario business will become part of Thermo Fisher's Laboratory Products and Biopharma Servic.

Thermo Fisher shares have declined ~20% YTD, presenting an attractive long-term entry point given its resilient business model and broad platform. TMO's diversified segments, recurring consumables revenue, and strong M&A track record underpin its competitive advantage across the life sciences value chain. Despite cautious FY26 guidance (4–6% revenue growth), TMO's EBITDA margin has normalized, and long-term demand drivers remain robust.

TMO's acquisitions and resilient pharma, biotech and diagnostics demand support growth, but currency swings and fierce competition remain risks.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, today announced the opening of its Cryo-Electron Microscopy (cryo-EM) Drug Discovery Center (CDDC) in South San Francisco. The new center provides pharmaceutical and biotechnology innovators with immersive, hands-on access to advanced cryo-EM technologies designed to accelerate structural insights and the development of life-saving therapies. Accelerating Drug Discovery with Cryo-EM The.

Thermo Fisher Scientific Inc. (TMO) Presents at 47th Annual Raymond James Institutional Investor Conference Transcript

During the quarter, Baron Health Care Fund added seven new positions and exited ten positions, bringing the number of positions in the Fund to 43. We bought shares of Arcutis Biotherapeutics, Inc., a biotechnology company that sells Zoryve cream and foam for the treatment of autoimmune dermatologic conditions. We sold Cidara Therapeutics, Inc. after the company announced it was being acquired by Merck for a substantial premium.